CannaPharmaRX files Form 12b-25 for late Q1 2026 10-Q

CannaPharmaRX, Inc. notified the SEC that it could not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 under Rule 12b-25 and intends to file the Form 10-Q within five calendar days of the prescribed due date.

Rhea-AI Filing Summary

CannaPharmaRX, Inc. notified the SEC that it could not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026 under Rule 12b-25 and intends to file the Form 10-Q within five calendar days of the prescribed due date. The notice cites delays in obtaining and compiling required information.

The filing discloses revenues of $627,462 for the three months ended March 31, 2026 versus $335,319 in 2025, and gross losses of $409,453 and $502,607, respectively; the company attributes revenue growth to expansion of its medical cannabis product line and new retail partners.

Insights

Corporate Reporting Analyst

Routine late‑filing notice citing internal compilation delays; financials show higher revenue with narrower gross loss.

The notification invokes Rule 12b-25 to request relief for a late Form 10-Q, stating the company will file within the five-calendar-day grace period. This is an administrative relief mechanism rather than an admission of substantive error.

Reported quarterly revenue rose to $627,462 and gross loss narrowed to $409,453 for Q1 2026; subsequent filings will provide the complete financial disclosures and reconciliations referenced in the notice.

Key Figures

Q1 2026 Revenue: $627,462 Q1 2025 Revenue: $335,319 Q1 2026 Gross Loss: $409,453 +3 more

6 metrics

Q1 2026 Revenue $627,462 three months ended March 31, 2026

Q1 2025 Revenue $335,319 three months ended March 31, 2025

Q1 2026 Gross Loss $409,453 three months ended March 31, 2026

Q1 2025 Gross Loss $502,607 three months ended March 31, 2025

Filing relief window five calendar days Rule 12b-25 grace period for Form 10-Q

Notice signed May 18, 2026 signature date by CFO Oliver Foeste

Key Terms

Rule 12b-25, Form 10-Q, gross loss

3 terms

Rule 12b-25 regulatory

"could not be filed within the prescribed time period"

Rule 12b-25 is an SEC filing provision that lets a company notify regulators and the public that it cannot file a required periodic report (like a quarterly or annual report) on time and explains the reason for the delay. For investors, the notice is a formal heads-up that financial information will arrive late—similar to a company calling to say it will be late turning in homework—so it signals increased uncertainty and may affect trading and risk assessments until the filing is available.

Form 10-Q regulatory

"Quarterly Report on Form 10-Q for the quarter ended March 31, 2026"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

gross loss financial

"the Company reported a gross loss of $409,453"

Gross loss is the total amount of money a business or investment lost before subtracting recoveries, insurance reimbursements, refunds, taxes, or other adjustments. Think of it as the sticker price of a loss—what was lost on paper before any offsets or fixes are applied—which helps investors see the raw scale of a problem and compare underlying performance across periods or peers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Why did CannaPharmaRX (CPMD) file a Form 12b-25?

The company filed Form 12b-25 because it could not complete its Form 10-Q due to delays in obtaining and compiling required information. It states the delay "could not be eliminated" without unreasonable effort and expense and will file within five calendar days.

When will CannaPharmaRX file the delayed Form 10-Q?

CannaPharmaRX states it will file the Form 10-Q no later than the fifth calendar day following the prescribed due date, per Rule 12b-25. The notice was signed on May 18, 2026 by the CFO, Oliver Foeste.

What revenue did CannaPharmaRX report for Q1 2026 and Q1 2025?

For the three months ended March 31, 2026, revenue was $627,462, compared with $335,319 for the same period in 2025. The company attributes growth to product expansion and new retail partners.

What were CannaPharmaRX's gross loss figures reported in the notice?

The notice reports a gross loss of $409,453 for the three months ended March 31, 2026 and $502,607 for the three months ended March 31, 2025, citing higher sales volumes as the primary reason for the improvement.

Does the Form 12b-25 indicate other overdue reports?

The Form 12b-25 includes a checkbox question about other periodic reports; the provided excerpt does not identify any other overdue periodic reports in the preceding 12 months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 02:43 PM EDT Learn about SEC filing dates

		OMB APPROVAL
		OMB Number: 3235-0058
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION	Expires: September 30, 2028
		Estimated average burden
	Washington, D.C. 20549	hours per response.......2.50
	FORM 12b-25	SEC FILE NUMBER
		000-27055
		CUSIP NUMBER
	NOTIFICATION OF LATE FILING	13765D109

(Check one):	☐	Form 10-K	☐	Form 20-F	☐	Form 11-K
	☒	Form 10-Q	☐	Form 10-D	☐	Form N-CEN	☐	Form N-CSR
	For Period Ended: March 31, 2026
	☐	Transition Report on Form 10-K
	☐	Transition Report on Form 20-F
	☐	Transition Report on Form 11-K
	☐	Transition Report on Form 10-Q
	For the Transition Period Ended: __________________________________________

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

PART I - REGISTRANT INFORMATION

CannaPharmaRX, Inc.

Full Name of Registrant

Former Name if Applicable

4439 Township Rd 304

Address of Principal Executive Office (Street and Number)

Mountain View County, Alberta, Canada T0M 0R0

City, State and Zip Code

PART II - RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

☒	(a)	The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

(Attach extra Sheets if Needed)

The Registrant could not complete the filing of its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 due to a delay in obtaining and compiling information required to be included in its Form 10-Q, which delay could not be eliminated by the Registrant without unreasonable effort and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, the Registrant will file its Form 10-Q no later than the fifth calendar day following the prescribed due date. 

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

Constantine Nkafu		(403)		637-0420
(Name)		(Area Code)		(Telephone Number)

(2)	Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). Yes ☒ No ☐
(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ☒ No ☐
	If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

During the three months ended March 31, 2026 and 2025, the Company reported revenues of $627,462 and $335,319, respectively. The increase was primarily driven by the continued expansion of the Company’s medical cannabis product line, improved distribution capabilities, increased market penetration, and the onboarding of new retail partners since late 2024.

During the three months ended March 31, 2026 and 2025, the Company reported a gross loss of $409,453 and $502,607, respectively. The decrease in gross loss was primarily due to higher sales volumes, which drove stronger revenue growth that outpaced the rise in cost of goods sold.

2

CannaPharmaRX, Inc. 

(Name of Registrant as Specified in Charter) 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized. 

Date: May 18, 2026	By:	/s/ Oliver Foeste
		Oliver Foeste
		Chief Financial Officer

3